OBJECTIVES: The present study aims to evaluate the antimicrobial property of Casiopeinas® copper- and ruthenium-based compounds against Aggregatibacter actinomycetemcomitans serotype b (ATCC® 43,718™), as well as the cytotoxicity on an osteoblasts cell line of both compounds. MATERIAL AND METHODS: The antibacterial effect of the copper-based compounds (CasII-gly, CasIII-ia) and the ruthenium-based compound (RuN-6) at four different concentrations was evaluated as the inhibition ratio of the bacterial growth after 48 h under anaerobic conditions, and the cell viability was measured through resazurin assay. RESULTS: The copper- and ruthenium-based compounds used for this assay were (CasII-gly, CasIII-ia, and RuN-6), showing inhibitory activity between 39 and 62% compared to the antibiotic employed as control 66%. Cell viability was established between 61 and 96%. CONCLUSIONS: Casiopeinas® and ruthenium showed dose and time dependent, inhibitory activity on A. actinomycetemcomitans, and low toxicity on cells (osteoblast) underexposure. The compound CasII-gly showed the best antimicrobial effect, and it could be considered a possible antimicrobial agent in periodontal therapy.
OBJECTIVES: The present study aims to evaluate the antimicrobial property of Casiopeinas® copper- and ruthenium-based compounds against Aggregatibacter actinomycetemcomitans serotype b (ATCC® 43,718™), as well as the cytotoxicity on an osteoblasts cell line of both compounds. MATERIAL AND METHODS: The antibacterial effect of the copper-based compounds (CasII-gly, CasIII-ia) and the ruthenium-based compound (RuN-6) at four different concentrations was evaluated as the inhibition ratio of the bacterial growth after 48 h under anaerobic conditions, and the cell viability was measured through resazurin assay. RESULTS: The copper- and ruthenium-based compounds used for this assay were (CasII-gly, CasIII-ia, and RuN-6), showing inhibitory activity between 39 and 62% compared to the antibiotic employed as control 66%. Cell viability was established between 61 and 96%. CONCLUSIONS: Casiopeinas® and ruthenium showed dose and time dependent, inhibitory activity on A. actinomycetemcomitans, and low toxicity on cells (osteoblast) underexposure. The compound CasII-gly showed the best antimicrobial effect, and it could be considered a possible antimicrobial agent in periodontal therapy.
Authors: Miguel A Vargas-Reus; Kaveh Memarzadeh; Jie Huang; Guogang G Ren; Robert P Allaker Journal: Int J Antimicrob Agents Date: 2012-06-21 Impact factor: 5.283
Authors: Christian Silva-Platas; Carlos Enrique Guerrero-Beltrán; Mariana Carrancá; Elena Cristina Castillo; Judith Bernal-Ramírez; Yuriana Oropeza-Almazán; Lorena N González; Rocío Rojo; Luis Enrique Martínez; Juan Valiente-Banuet; Lena Ruiz-Azuara; María Elena Bravo-Gómez; Noemí García; Karla Carvajal; Gerardo García-Rivas Journal: J Bioenerg Biomembr Date: 2016-01-07 Impact factor: 2.945
Authors: João S Fernandes; Piergiorgio Gentile; Ricardo A Pires; Rui L Reis; Paul V Hatton Journal: Acta Biomater Date: 2017-07-01 Impact factor: 8.947
Authors: Panos N Papapanou; Mariano Sanz; Nurcan Buduneli; Thomas Dietrich; Magda Feres; Daniel H Fine; Thomas F Flemmig; Raul Garcia; William V Giannobile; Filippo Graziani; Henry Greenwell; David Herrera; Richard T Kao; Moritz Kebschull; Denis F Kinane; Keith L Kirkwood; Thomas Kocher; Kenneth S Kornman; Purnima S Kumar; Bruno G Loos; Eli Machtei; Huanxin Meng; Andrea Mombelli; Ian Needleman; Steven Offenbacher; Gregory J Seymour; Ricardo Teles; Maurizio S Tonetti Journal: J Clin Periodontol Date: 2018-06 Impact factor: 8.728
Authors: Alejandra Idan Valencia-Cruz; Laura I Uribe-Figueroa; Rodrigo Galindo-Murillo; Karol Baca-López; Anllely G Gutiérrez; Adriana Vázquez-Aguirre; Lena Ruiz-Azuara; Enrique Hernández-Lemus; Carmen Mejía Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240